Displaying all 3 publications

Abstract:
Sort:
  1. Fulltext Silicone pneumonitis after gluteal filler: a case report and literature review
    Ng BH, Mat WRW, Abeed NNN, Hamid MFA, Yu-Lin AB, Soo CI
    Respirol Case Rep, 2020 Apr;8(3):e00538.
    PMID: 32076554 DOI: 10.1002/rcr2.538
    Liquid silicone (polydimethylsiloxane) is an inert material that is commonly used for cosmetic purpose. Silicone embolization syndrome (SES) can rapidly progress to pneumonitis as a consequence of the injection of nonmedical-grade liquid silicone. We describe a case of severe silicone pneumonitis complicated with acute respiratory distress syndrome and bilateral pneumothorax secondary to silicone gluteal augmentation. In this case report, we aim to discuss our experience and approach in managing an uncommon case of SES.
  2. Fulltext Impact of Aerobika® oscillating positive expiratory pressure in improving small airway resistance, lung function, symptoms and exercise capacity in chronic obstructive pulmonary disease
    Sahardin SN, Jailaini MFM, Abeed NNN, Ban AY, Hau NB, Azmel AA, et al.
    Front Med (Lausanne), 2023;10:1202380.
    PMID: 37332765 DOI: 10.3389/fmed.2023.1202380
    BACKGROUND: Aerobika® oscillating positive expiratory pressure (OPEP) device promotes airway clearance in many respiratory diseases. However, studies have yet to focus on its effectiveness in improving small airway resistance via impulse oscillometry (IOS) measurement in COPD subjects. We aim to evaluate the improvement of small airway resistance (via IOS), lung function (spirometry), exercise capacity [via 6-min walking test (6MWT)], symptoms [COPD assessment test (CAT)] and severe exacerbation events among COPD subjects using Aerobika® OPEP.

    METHODS: This was a prospective, single-arm interventional study among COPD subjects with small airway disease. Subjects were instructed to use twice daily Aerobika® OPEP (10 min each session); for 24 weeks; as an additional to standard therapy. IOS, spirometry, 6MWT, CAT score and severe exacerbation events were evaluated at baseline, 12 weeks and 24 weeks.

    RESULTS: Fifty-three subjects completed the study. Aerobika® usage showed improvement of IOS parameters; e.g. measurement of airway resistance at 5 Hz (R5), cmH20/L/s, (12-week p = 0.008, 24-week p 

  3. Fulltext Correction: Modified regimen intrapleural alteplase with pulmozyme in pleural infection management: a tertiary teaching hospital experience
    Cheong XK, Ban AY, Ng BH, Abeed NNN, Ismail NAN, Fuad NFN, et al.
    BMC Pulm Med, 2022 Nov 23;22(1):440.
    PMID: 36418993 DOI: 10.1186/s12890-022-02251-0
Related Terms
    Try searching for something
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links